Pharvaris N.V. (PHVS)
NASDAQ: PHVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PHVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.21B
- EPS (TTM)
- -$3.13
- Dividend yield
- None
- 52-week range
- 23.15 – 43.25
- Day range
- 30.43 – 31.99
- Volume / Avg
- 464.00K / 756.20K
- Beta
- —
- Shares outstanding
- 70.79M
52-week range
PHVS stock today
Pharvaris N.V. (PHVS) closed at $31.28 on Nov 20, down 1.20% (-$0.38), versus the S&P 500's 3.70% decline. Shares are 27.7% below their 52-week high of $43.25, set on Sep 8, 2026 and 35.1% above the 52-week low of $23.15, in the middle of the past year's range. PHVS is up 12.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 26.0%.
Pharvaris N.V. has posted a net loss over the last twelve months (EPS of -$3.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pharvaris N.V.
Company profilePharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Berndt Axel Edvard Modig CPA, M.B.A.
- Headquarters
- Zug
- Employees
- 168
- IPO year
- 2021
- Website
- pharvaris.com
Financial highlights
Full financialsPharvaris N.V. reported a net loss of $26.0 million, compared with a loss of $8.0 million a year earlier.
| Fiscal year | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-25.99M | $-8.03M | $-4.31M |
| EPS (diluted) | — | — | — |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$58.27+86.29%
- Strong buy 3
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.77 vs $-0.82
- Surprise
- +6.10%
PHVS news
All PHVS news- Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingGlobeNewswire
- Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingGlobeNewswire
- Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027NasdaqPHVS, ET
- Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetGlobeNewswire
- iShares Core MSCI Europe ETF Experiences Big InflowNasdaqIEUR, AER, BWLP, PHVS
- Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTHNasdaqATRC, BLSM, FTH, PHVS
- 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & AtaraNasdaqATRA, BJDX, PDSB, PHVS
Pharvaris N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Company N.V. | 18.41 | -5.64% | $2.21B | vs PHVS |
| PRGOPerrigo Company plc | 15.94 | -0.62% | $2.21B | vs PHVS |
| LKFTLakefront Biotherapeutics ADR | 33.31 | -0.24% | $2.18B | vs PHVS |
| RCUSArcus Biosciences Inc. | 15.62 | -1.01% | $2.25B | vs PHVS |
| HCMHUTCHMED (China) Limited ADR | 13.22 | -1.71% | $2.30B | vs PHVS |
| PVLAPalvella Therapeutics Inc. | 142.85 | -2.00% | $2.09B | vs PHVS |
| PBHPrestige Consumer Healthcare Inc. | 49.63 | +0.06% | $2.35B | vs PHVS |
| AUPHAurinia Pharmaceuticals Inc | 14.70 | -1.28% | $1.97B | vs PHVS |
Indexes, lists and sector
Pharvaris N.V. stock FAQ
What is Pharvaris N.V.'s stock price today?
PHVS last traded at $31.28 as of Nov 20, 4:00 PM EST, down 1.20% on the day. Prices are delayed at least 15 minutes.
Who is Pharvaris N.V.'s CEO?
Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V., which has about 168 employees.
What is the PHVS 52-week high?
The 52-week high for PHVS is $43.25 and the 52-week low is $23.15. The stock is currently 27.7% below its high.